|Bid||20.56 x 800|
|Ask||20.58 x 1400|
|Day's Range||20.54 - 21.62|
|52 Week Range||11.75 - 27.68|
|Beta (5Y Monthly)||1.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.44|
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -304.76% and -46.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Dicerna presents positive clinical data for investigational treatments RG6346 for chronic HBV and Nedosiran for PH and preclinical data in new tissues
Dicerna today reported its financial results for the second quarter ended June 30, 2020.